<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109364</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001770</org_study_id>
    <nct_id>NCT05109364</nct_id>
  </id_info>
  <brief_title>Terazosin and Parkinson's Disease Extension Study</brief_title>
  <official_title>The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the long-term effects of treatment with the&#xD;
      selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects&#xD;
      with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging&#xD;
      changes will be correlated to the presence and severity of motor and non-motor symptoms of&#xD;
      PD, measured by validated clinical scales and cardiac autonomic function tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the long-term effects of treatment with the&#xD;
      selective post-synaptic a1-adrenergic blocker terazosin on serial 123I-FP-CIT DAT-SPECT in a&#xD;
      population of subjects with defined pre-motor PD risks (i.e., RBD and at least one among&#xD;
      hyposmia, constipation, depression and color vision abnormality) and abnormal 123I-MIBG&#xD;
      uptake. Imaging changes will be correlated to the presence and severity of motor and&#xD;
      non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic&#xD;
      function tests. The rate of RBD clinical phenoconversion to PD will be estimated and compared&#xD;
      to available data in the literature.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in 123I-MIBG reuptake</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>123I-MIBG reuptake will be measured by early and late Heart to Mediastinal ratio (H/M) and Washout ratio (WR) which will be calculated using the following formula: [(early heart counts/pixel - early mediastinum counts/pixel) - (late heart counts/pixel decay-corrected - late mediastinum counts/pixel decay-corrected)]/(early heart counts/pixel - early mediastinum counts/pixel). Care will be taken to exclude lung or liver from the myocardial and large vessels and lung from the mediastinum region of interest. MIBG abnormality cutoffs will be set for values of late H/M &lt;2.2 and WR &gt;30%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of PD or other synucleinopathies by the end of 3 years in the study population</measure>
    <time_frame>3 years</time_frame>
    <description>Diagnosis of PD will be defined or ruled out according to the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 123I-Ioflupane uptake</measure>
    <time_frame>Every year for three years</time_frame>
    <description>Measured by 123I-Ioflupane uptake, between baseline, year one, year two and year three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of DAT Scan compared to MIBG in predicting RBD conversion to PD/other synucleinopathies</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability Analysis (HRV) compared to MIBG results in predicting RBD convertion to PD/other synucleinopathies</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>Beat-to-beat intervals (in milliseconds) will be registered using Polar V800 (PolarÂ®) for twenty minutes every 6 months for 3 years. This measurement will be used for HRV analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III changes from OFF medication between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>The Movement disorder society-unified Parkinson's disease rating scale (MDS-UPDRS) Part III will be administered at baseline and 26 weeks after study medication titration. Each item of the MDS-UPDRS has a possible rating from 0 to 4, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.Clinical scales will be performed OFF medication in those subjects that might be receiving dopaminergic drugs</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-Motor Symptoms Scale (NMSS) changes between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>The NMSS measures non-motor symptoms over the previous month. Each symptom is scored with respect to: Severity: 0 = None, 1 = Mild; 2 = Moderate; 3 = Severe and Frequency: 1 = Rarely (&lt;1/wk); 2 = Often (1/wk); 3 = Frequent (several times per week); 4 = Very Frequent (daily or all the time).</description>
  </other_outcome>
  <other_outcome>
    <measure>Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) changes between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>The SCOPA-AUT scale consists of 25 items assessing autonomic symptoms in the following regions: gastrointestinal (7), urinary (6), cardiovascular (3), thermoregulatory (4), pupillomotor (1), and sexual (2 items for men and 2 items for women) dysfunction.</description>
  </other_outcome>
  <other_outcome>
    <measure>REM sleep Behavior Disorder Screening questionnaire (RBDSQ) changes between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>RBD questionnaire (RBDSQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Smell changes as measured by University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>University of Pennsylvania Smell Identification Test (UPSIT) changes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional constipation score changes between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>Functional constipation will be assessed at screening and at 26 weeks after study medication titration using a questionnaire based on modified ROME III diagnostic criteria, which focuses on symptoms including straining, lumpy or hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction or blockage, manual maneuvers to facilitate evacuation, and two or fewer bowel movements per week. This questionnaire is based on a six item self-report measures with a three point summated rating scale. The total score has a range of 0 to 12, with scores &gt; 4 identifying functional constipation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Color vision changes, as assessed using HRR Pseudoisochromatic Plates, between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>Color vision changes will be assessed using HRR Pseudochromatic Plates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Central insulin resistance changes between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>Measures of insulin sensitivity in neuronal-origin enriched plasma EVs (central IR) will be used to test the association of changes in such sensitivity to changes in MIBG uptake and clinical scores. For that purpose, plasma samples will be collected and stored and -80oC to allow for isolation of neuronal origin EVs at the completion of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Differences in integrity of pigmented neurons in the locus coeruleus and substantia nigra between baseline, year one, year two and year three</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome will be measured by the content of neuromelanin, a product of cathecolamine metabolism in LC and SN.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between changes in integrity of pigmented neurons of substantia nigra as measured by neuromelanin-sensitive magnetic resonance imaging (MRI) and 123I-Ioflupane uptake as measured by Dopamine Transporter Imaging (DAT scan)</measure>
    <time_frame>3 years</time_frame>
    <description>These measurements will be aggregated to calculate the correlation between changes in neuromelanin content as measured by NM-MRI and dopamine content as measured by DAT scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Variability (HRV) changes between baseline and every 6 months for three years</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral insulin resistance (IR) changes between baseline and every 6 months for three years.</measure>
    <time_frame>Every 6 months for 3 years</time_frame>
    <description>Peripheral IR will be defined by the homeostase model assessment of IR (HOMA-IR) defined as fasting glucose (mmol/L) x fasting insulin (mU/mL)/22.5. A cutoff HOMA index of 2.0, equivalent to &lt;50% sensitivity, will be used to define IR. Subjects will be considered to have IR if they either have a HOMAâ¥2.0 and/or HbA1câ¥5.7</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Symptomatic Parkinson Disease</condition>
  <condition>REM Sleep Behavior Disorder</condition>
  <condition>Pre-motor Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>terazosin therapy extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin medication. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the alpha1- adrenergic receptor antagonist terazosin, resulting in a decreased clinical phenoconversion rate to parkinsonism.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terazosin therapy</intervention_name>
    <description>Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical phenoconversion rate to parkinsonism.</description>
    <arm_group_label>terazosin therapy extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrolled in the study &quot;The Effect of alpha1- adrenergic receptor antagonist Therapy on&#xD;
             Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's&#xD;
             Disease&quot; (STUDY #000540)&#xD;
&#xD;
          -  Capacity to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary Parkinsonism, including tardive&#xD;
&#xD;
          -  Concurrent dementia defined by a score lower than 22 on the MoCA&#xD;
&#xD;
          -  Concurrent severe depression defined by a BDI fast screen score greater than 13&#xD;
&#xD;
          -  Comorbidities related to SNS hyperactivity&#xD;
&#xD;
          -  Heart failure (LVEF &lt;45%)&#xD;
&#xD;
          -  Recent myocardial revascularization (&lt;12 weeks)&#xD;
&#xD;
          -  Hypertension (SBP&gt;150mmHg or DBP&gt;100mmHg)&#xD;
&#xD;
          -  Chronic Atrial fibrillation&#xD;
&#xD;
          -  Concurrent Use of Beta-adrenergic antagonist&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  Untreated Sever Sleep Apnea; Apnea-Hypopnea Index (AHI) &gt; 30/h.&#xD;
&#xD;
          -  Severely reduced kidney function (Glomerular Filtration Rate&lt;30ml/min)&#xD;
&#xD;
          -  Contraindications to the use of terazosin&#xD;
&#xD;
          -  Recent myocardial infarction (&lt;48 h)&#xD;
&#xD;
          -  Ongoing angina pectoris&#xD;
&#xD;
          -  Cardiogenic shock or prolonged hypotension&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil&#xD;
             (CialisTM), or vardenafil (LevitraTM)&#xD;
&#xD;
          -  History of priapism (persistent and painful erection)&#xD;
&#xD;
          -  Neurogenic orthostatic hypotension defined as symptomatic decrease in BP &gt; 20mmHg&#xD;
             systolic or &gt; 10mmHg diastolic and HR increase &lt; 20bpm on supine to sitting or&#xD;
             standing.&#xD;
&#xD;
          -  Blood pressure less than 110 mm Hg systolic at screening or baseline visit&#xD;
&#xD;
          -  Use of investigational drugs within 30 days before screening&#xD;
&#xD;
          -  For female participant, pregnancy, or plans for child-bearing during study period&#xD;
&#xD;
          -  Allergy/hypersensitivity to iodine or study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Tagliati, MD, FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Gregorio, PhD</last_name>
    <phone>424-315-0021</phone>
    <phone_ext>50021</phone_ext>
    <email>michele.gregorio@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gloria Obialisi, MS</last_name>
    <phone>310-423-1704</phone>
    <phone_ext>1704</phone_ext>
    <email>gloria.obialisi@cshs.org</email>
  </overall_contact_backup>
  <results_reference>
    <citation>American Academy of Sleep Medicine. International classification of sleep disor- ders 2nd ed.: Diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine; 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005 Jan;15(1):29-34.</citation>
    <PMID>15779234</PMID>
  </results_reference>
  <results_reference>
    <citation>Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010 Jan;1184:15-54. doi: 10.1111/j.1749-6632.2009.05115.x. Review.</citation>
    <PMID>20146689</PMID>
  </results_reference>
  <results_reference>
    <citation>Braak H, Del Tredici K, RÃ¼b U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211.</citation>
    <PMID>12498954</PMID>
  </results_reference>
  <results_reference>
    <citation>Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987.</citation>
    <PMID>31524631</PMID>
  </results_reference>
  <results_reference>
    <citation>Cedarbaum JM, Aghajanian GK. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol. 1977 Aug 15;44(4):375-85.</citation>
    <PMID>330174</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang EB, Leung PS. Gastrintestinal Motility. In 'The Gastrointestinal System: Gastrointestinal, Nutritional and Hepatobiliary Physiology' P.S. Leung (ed.), Springer Science, Dordrecht 2014, 35-62.</citation>
  </results_reference>
  <results_reference>
    <citation>Clewett DV, Lee TH, Greening S, Ponzio A, Margalit E, Mather M. Neuromelanin marks the spot: identifying a locus coeruleus biomarker of cognitive reserve in healthy aging. Neurobiol Aging. 2016 Jan;37:117-126. doi: 10.1016/j.neurobiolaging.2015.09.019. Epub 2015 Oct 29.</citation>
    <PMID>26521135</PMID>
  </results_reference>
  <results_reference>
    <citation>de Milliano PA, van Eck-Smit BL, de Groot AC, Lie KI. Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease. Circulation. 2000 Nov 14;102(20):2553-4.</citation>
    <PMID>11076832</PMID>
  </results_reference>
  <results_reference>
    <citation>de Peuter OR, Verberne HJ, Kok WE, van den Bogaard B, Schaap MC, Nieuwland R, Meijers JC, Somsen GA, Bakx A, Kamphuisen PW. Differential effects of nonselective versus selective Î²-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure. J Nucl Med. 2013 Oct;54(10):1733-9. doi: 10.2967/jnumed.113.120477. Epub 2013 Aug 22.</citation>
    <PMID>23970363</PMID>
  </results_reference>
  <results_reference>
    <citation>Dinan TG, Cryan JF. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology. 2012 Sep;37(9):1369-78. doi: 10.1016/j.psyneuen.2012.03.007. Epub 2012 Apr 5. Review.</citation>
    <PMID>22483040</PMID>
  </results_reference>
  <results_reference>
    <citation>Dorschner J, Farmakis G, Behnke S, Hellwig D, Schneider S, Fassbender K, Kirsch CM, Dillmann U, Spiegel J. Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2011 Jun;17(5):372-5. doi: 10.1016/j.parkreldis.2011.03.001. Epub 2011 Mar 21.</citation>
    <PMID>21421334</PMID>
  </results_reference>
  <results_reference>
    <citation>Fereshtehnejad SM, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB. Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord. 2017 Jun;32(6):865-873. doi: 10.1002/mds.26989. Epub 2017 Apr 21.</citation>
    <PMID>28429825</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO 3rd. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000 Sep 5;133(5):338-47.</citation>
    <PMID>10979878</PMID>
  </results_reference>
  <results_reference>
    <citation>Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W. Î²2-adrenoceptor agonists and antagonists and risk of Parkinson's disease. Mov Disord. 2018 Sep;33(9):1465-1471. doi: 10.1002/mds.108.</citation>
    <PMID>30311974</PMID>
  </results_reference>
  <results_reference>
    <citation>Halsband C, Zapf A, Sixel-DÃ¶ring F, Trenkwalder C, Mollenhauer B. The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease. Mov Disord Clin Pract. 2018 Mar 1;5(2):171-176. doi: 10.1002/mdc3.12591. eCollection 2018 Mar-Apr.</citation>
    <PMID>30009211</PMID>
  </results_reference>
  <results_reference>
    <citation>He SC, Niu Q. Subclinical neurophysiological effects of manganese in welding workers. Int J Immunopathol Pharmacol. 2004 May-Aug;17(2 Suppl):11-6.</citation>
    <PMID>15345186</PMID>
  </results_reference>
  <results_reference>
    <citation>Heffernan DS, Inaba K, Arbabi S, Cotton BA. Sympathetic hyperactivity after traumatic brain injury and the role of beta-blocker therapy. J Trauma. 2010 Dec;69(6):1602-9. doi: 10.1097/TA.0b013e3181f2d3e8. Review.</citation>
    <PMID>21045744</PMID>
  </results_reference>
  <results_reference>
    <citation>Hogg E, Athreya K, Basile C, Tan EE, Kaminski J, Tagliati M. High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson's Disease. J Parkinsons Dis. 2018;8(2):259-265. doi: 10.3233/JPD-181305.</citation>
    <PMID>29614702</PMID>
  </results_reference>
  <results_reference>
    <citation>Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1288-1295. doi: 10.1136/jnnp-2018-318275. Epub 2018 Aug 3.</citation>
    <PMID>30076266</PMID>
  </results_reference>
  <results_reference>
    <citation>Iranzo A, Santamaria J. Bisoprolol-induced rapid eye movement sleep behavior disorder. Am J Med. 1999 Oct;107(4):390-2.</citation>
    <PMID>10527042</PMID>
  </results_reference>
  <results_reference>
    <citation>Iranzo A, Valldeoriola F, LomeÃ±a F, Molinuevo JL, Serradell M, Salamero M, Cot A, Ros D, PavÃ­a J, Santamaria J, Tolosa E. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011 Sep;10(9):797-805. doi: 10.1016/S1474-4422(11)70152-1. Epub 2011 Jul 28.</citation>
    <PMID>21802993</PMID>
  </results_reference>
  <results_reference>
    <citation>Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, LomeÃ±a F, Vilas D, LladÃ³ A, Gaig C, Santamaria J. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013 May;12(5):443-53. doi: 10.1016/S1474-4422(13)70056-5. Epub 2013 Apr 3.</citation>
    <PMID>23562390</PMID>
  </results_reference>
  <results_reference>
    <citation>Iranzo A, LomeÃ±a F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, Serradell M, Duch J, PavÃ­a J, Gallego J, Seppi K, HÃ¶gl B, Tolosa E, Poewe W, Santamaria J; Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 2010 Nov;9(11):1070-7. doi: 10.1016/S1474-4422(10)70216-7. Epub 2010 Sep 16. Erratum in: Lancet Neurol. 2010 Nov;9(11):1045.</citation>
    <PMID>20846908</PMID>
  </results_reference>
  <results_reference>
    <citation>Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology. 1999 Apr 12;52(6):1269-71.</citation>
    <PMID>10214756</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996 Apr;14(4):489-94. Erratum in: J Hypertens 1996 Nov;14(11):1382.</citation>
    <PMID>8761899</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J; ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010 May 18;55(20):2212-21. doi: 10.1016/j.jacc.2010.01.014. Epub 2010 Feb 25.</citation>
    <PMID>20188504</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. Trends Neurosci. 2019 Jan;42(1):4-13. doi: 10.1016/j.tins.2018.09.007. Epub 2018 Oct 17. Review.</citation>
    <PMID>30342839</PMID>
  </results_reference>
  <results_reference>
    <citation>Joyner MJ, Barnes JN, Hart EC, Wallin BG, Charkoudian N. Neural control of the circulation: how sex and age differences interact in humans. Compr Physiol. 2015 Jan;5(1):193-215. doi: 10.1002/cphy.c140005. Review.</citation>
    <PMID>25589269</PMID>
  </results_reference>
  <results_reference>
    <citation>Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003;63(16):1697-741. Review.</citation>
    <PMID>12904089</PMID>
  </results_reference>
  <results_reference>
    <citation>Keren NI, Taheri S, Vazey EM, Morgan PS, Granholm AC, Aston-Jones GS, Eckert MA. Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. Neuroimage. 2015 Jun;113:235-45. doi: 10.1016/j.neuroimage.2015.03.020. Epub 2015 Mar 17.</citation>
    <PMID>25791783</PMID>
  </results_reference>
  <results_reference>
    <citation>Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, Nahimi A, Stokholm MG, Pavese N, Beier CP, Brooks DJ, Borghammer P. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018 Jul;17(7):618-628. doi: 10.1016/S1474-4422(18)30162-5. Epub 2018 Jun 1.</citation>
    <PMID>29866443</PMID>
  </results_reference>
  <results_reference>
    <citation>Langston JW, Wiley JC, Tagliati M. Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm. NPJ Parkinsons Dis. 2018 Feb 23;4:5. doi: 10.1038/s41531-018-0041-9. eCollection 2018. Review.</citation>
    <PMID>29507872</PMID>
  </results_reference>
  <results_reference>
    <citation>LÃ¶tsch J, Daiker H, HÃ¤hner A, Ultsch A, Hummel T. Drug-target based cross-sectional analysis of olfactory drug effects. Eur J Clin Pharmacol. 2015 Apr;71(4):461-71. doi: 10.1007/s00228-015-1814-2. Epub 2015 Feb 11.</citation>
    <PMID>25666029</PMID>
  </results_reference>
  <results_reference>
    <citation>Mann DM, Yates PO. Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain. 1974 Sep;97(3):489-98.</citation>
    <PMID>4423478</PMID>
  </results_reference>
  <results_reference>
    <citation>Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996 Jan;46(1):231-7.</citation>
    <PMID>8559382</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinelli N, Olivieri O, Girelli D. Air particulate matter and cardiovascular disease: a narrative review. Eur J Intern Med. 2013 Jun;24(4):295-302. doi: 10.1016/j.ejim.2013.04.001. Epub 2013 May 4. Review.</citation>
    <PMID>23647842</PMID>
  </results_reference>
  <results_reference>
    <citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.</citation>
    <PMID>3899825</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitsui J, Saito Y, Momose T, Shimizu J, Arai N, Shibahara J, Ugawa Y, Kanazawa I, Tsuji S, Murayama S. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006 Apr 15;243(1-2):101-4. Epub 2006 Jan 27.</citation>
    <PMID>16442563</PMID>
  </results_reference>
  <results_reference>
    <citation>Miyamoto T, Miyamoto M, Inoue Y, Usui Y, Suzuki K, Hirata K. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006 Dec 26;67(12):2236-8.</citation>
    <PMID>17190953</PMID>
  </results_reference>
  <results_reference>
    <citation>Mizutani Y, Nakamura T, Okada A, Suzuki J, Watanabe H, Hirayama M, Sobue G. Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 May;20(5):520-4. doi: 10.1016/j.parkreldis.2014.02.010. Epub 2014 Feb 20.</citation>
    <PMID>24637128</PMID>
  </results_reference>
  <results_reference>
    <citation>Morrison I, Frangulyan R, Riha RL. Beta-blockers as a cause of violent rapid eye movement sleep behavior disorder: a poorly recognized but common cause of violent parasomnias. Am J Med. 2011 Jan;124(1):e11. doi: 10.1016/j.amjmed.2010.04.023. Epub 2010 Sep 29.</citation>
    <PMID>20887968</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakajo M, Shapiro B, Glowniak J, Sisson JC, Beierwaltes WH. Inverse relationship between cardiac accumulation of meta-[131I]iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med. 1983 Dec;24(12):1127-34.</citation>
    <PMID>6644373</PMID>
  </results_reference>
  <results_reference>
    <citation>Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K. Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. Sleep Med. 2011 Aug;12(7):711-3. doi: 10.1016/j.sleep.2011.01.015. Epub 2011 Jun 22.</citation>
    <PMID>21700495</PMID>
  </results_reference>
  <results_reference>
    <citation>Nul D, Zambrano C, Diaz A, Ferrante D, Varini S, Soifer S, Grancelli H, Doval H; Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovasc Drugs Ther. 2005 Mar;19(2):125-34.</citation>
    <PMID>16025231</PMID>
  </results_reference>
  <results_reference>
    <citation>Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):189-94.</citation>
    <PMID>10406987</PMID>
  </results_reference>
  <results_reference>
    <citation>Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain. 2008 Mar;131(Pt 3):642-50. Epub 2007 Dec 13.</citation>
    <PMID>18079166</PMID>
  </results_reference>
  <results_reference>
    <citation>Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012 Jun;18(5):494-500. doi: 10.1016/j.parkreldis.2012.01.009. Epub 2012 Feb 8. Review.</citation>
    <PMID>22321865</PMID>
  </results_reference>
  <results_reference>
    <citation>Otsuka N, Ohi M, Chin K, Kita H, Noguchi T, Hata T, Nohara R, Hosokawa R, Fujita M, Kuno K. Assessment of cardiac sympathetic function with iodine-123-MIBG imaging in obstructive sleep apnea syndrome. J Nucl Med. 1997 Apr;38(4):567-72.</citation>
    <PMID>9098203</PMID>
  </results_reference>
  <results_reference>
    <citation>Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.</citation>
    <PMID>8614419</PMID>
  </results_reference>
  <results_reference>
    <citation>Pagano G, Tan EE, Haider J, Bautista A and Tagliati M. Constipation is reduced in Parkinson's disease patients treated with beta-blockers: A case report and retrospective analysis of a large cohort. Park Relat Disord 2015;21(2):120-5.</citation>
  </results_reference>
  <results_reference>
    <citation>Postuma RB, Montplaisir J, Lanfranchi P, Blais H, RomprÃ© S, Colombo R, Gagnon JF. Cardiac autonomic denervation in Parkinson's disease is linked to REM sleep behavior disorder. Mov Disord. 2011 Jul;26(8):1529-33. doi: 10.1002/mds.23677. Epub 2011 Apr 29.</citation>
    <PMID>21538520</PMID>
  </results_reference>
  <results_reference>
    <citation>Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012 Apr 15;27(5):617-26. doi: 10.1002/mds.24996. Review.</citation>
    <PMID>22508280</PMID>
  </results_reference>
  <results_reference>
    <citation>Postuma RB, Gagnon JF, Bertrand JA, GÃ©nier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015 Mar 17;84(11):1104-13. doi: 10.1212/WNL.0000000000001364. Epub 2015 Feb 13.</citation>
    <PMID>25681454</PMID>
  </results_reference>
  <results_reference>
    <citation>Pyatigorskaya N, Gaurav R, Arnaldi D, Leu-Semenescu S, Yahia-Cherif L, Valabregue R, Vidailhet M, Arnulf I, LehÃ©ricy S. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Sleep. 2017 Nov 1;40(11). doi: 10.1093/sleep/zsx149.</citation>
    <PMID>28958075</PMID>
  </results_reference>
  <results_reference>
    <citation>Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord. 2014 Mar;20(3):267-73. doi: 10.1016/j.parkreldis.2013.11.001. Epub 2013 Nov 21. Review.</citation>
    <PMID>24332912</PMID>
  </results_reference>
  <results_reference>
    <citation>Sakata K, Shirotani M, Yoshida H, Kurata C. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J Nucl Med. 1999 Jan;40(1):6-11.</citation>
    <PMID>9935049</PMID>
  </results_reference>
  <results_reference>
    <citation>Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport. 2006 Jul 31;17(11):1215-8.</citation>
    <PMID>16837857</PMID>
  </results_reference>
  <results_reference>
    <citation>Scheer FA, Morris CJ, Garcia JI, Smales C, Kelly EE, Marks J, Malhotra A, Shea SA. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep. 2012 Oct 1;35(10):1395-402.</citation>
    <PMID>23024438</PMID>
  </results_reference>
  <results_reference>
    <citation>Scott LA, Kench PL. Cardiac autonomic neuropathy in the diabetic patient: does 123I-MIBG imaging have a role to play in early diagnosis? J Nucl Med Technol. 2004 Jun;32(2):66-71. Review.</citation>
    <PMID>15175402</PMID>
  </results_reference>
  <results_reference>
    <citation>Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA. Î²2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018 Nov;84(5):683-693. doi: 10.1002/ana.25341. Epub 2018 Oct 30.</citation>
    <PMID>30225948</PMID>
  </results_reference>
  <results_reference>
    <citation>Seravalle G, Piperno A, Mariani R, Pelloni I, Facchetti R, Dell'Oro R, Cuspidi C, Mancia G, Grassi G. Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study. Eur Heart J. 2016 Mar 21;37(12):988-95. doi: 10.1093/eurheartj/ehv696. Epub 2015 Dec 28.</citation>
    <PMID>26715163</PMID>
  </results_reference>
  <results_reference>
    <citation>Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996 Feb;46(2):388-93. Erratum in: Neurology 1996 Jun;46(6):1787.</citation>
    <PMID>8614500</PMID>
  </results_reference>
  <results_reference>
    <citation>Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013 Aug;14(8):744-8. doi: 10.1016/j.sleep.2012.10.009. Epub 2013 Jan 22.</citation>
    <PMID>23347909</PMID>
  </results_reference>
  <results_reference>
    <citation>Spiegel J, MÃ¶llers MO, Jost WH, Fuss G, Samnick S, Dillmann U, Becker G, Kirsch CM. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord. 2005 May;20(5):552-61.</citation>
    <PMID>15645531</PMID>
  </results_reference>
  <results_reference>
    <citation>Spiegel J, Hellwig D, Samnick S, Jost W, MÃ¶llers MO, Fassbender K, Kirsch CM, Dillmann U. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm (Vienna). 2007 Mar;114(3):331-5. Epub 2006 May 24.</citation>
    <PMID>16715205</PMID>
  </results_reference>
  <results_reference>
    <citation>Spiegel J, Hellwig D, Jost WH, Farmakis G, Samnick S, Fassbender K, Kirsch CM, Dillmann U. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. Open Neurol J. 2007;1:1-4. doi: 10.2174/1874205X00701010001. Epub 2007 Aug 22.</citation>
    <PMID>19018276</PMID>
  </results_reference>
  <results_reference>
    <citation>Stoschitzky K, Koshucharova G, Lercher P, Maier R, Sakotnik A, Klein W, Liebmann PM, Lindner W. Stereoselective effects of (R)- and (S)-carvedilol in humans. Chirality. 2001 Jul;13(7):342-6.</citation>
    <PMID>11400186</PMID>
  </results_reference>
  <results_reference>
    <citation>Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, Tonami N. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med. 2000 May;27(5):566-73.</citation>
    <PMID>10853813</PMID>
  </results_reference>
  <results_reference>
    <citation>Travin MI, Matsunari I, Thomas GS, Nakajima K, Yoshinaga K. How do we establish cardiac sympathetic nervous system imaging with (123)I-mIBG in clinical practice? Perspectives and lessons from Japan and the US. J Nucl Cardiol. 2019 Aug;26(4):1434-1451. doi: 10.1007/s12350-018-1394-5. Epub 2018 Sep 3.</citation>
    <PMID>30178272</PMID>
  </results_reference>
  <results_reference>
    <citation>Treglia G, Stefanelli A, Bruno I, Giordano A. Clinical usefulness of myocardial innervation imaging using Iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: an overview. Eur Rev Med Pharmacol Sci. 2013 Jan;17(1):56-68. Review.</citation>
    <PMID>23329524</PMID>
  </results_reference>
  <results_reference>
    <citation>Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord. 2010 Oct 30;25(14):2296-303. doi: 10.1002/mds.23348.</citation>
    <PMID>20976736</PMID>
  </results_reference>
  <results_reference>
    <citation>Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu OL, Kluge A, Knudsen GM, Koulibaly PM, Nobili F, Pagani M, Sabri O, Vander Borght T, Van Laere K, Tatsch K. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):213-27. doi: 10.1007/s00259-012-2276-8. Epub 2012 Nov 16.</citation>
    <PMID>23160999</PMID>
  </results_reference>
  <results_reference>
    <citation>Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011 Dec;17(10):724-9. doi: 10.1016/j.parkreldis.2011.04.016. Epub 2011 May 14. Review.</citation>
    <PMID>21571570</PMID>
  </results_reference>
  <results_reference>
    <citation>Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008 May;29(9):1147-59. doi: 10.1093/eurheartj/ehn113. Epub 2008 Mar 17. Review.</citation>
    <PMID>18349024</PMID>
  </results_reference>
  <results_reference>
    <citation>Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, Otto CA, Swanson DP, Beierwaltes WH. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981 Jan;22(1):22-31.</citation>
    <PMID>7452352</PMID>
  </results_reference>
  <results_reference>
    <citation>Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol. 2001 Dec;54(6):414-8. Review.</citation>
    <PMID>11724917</PMID>
  </results_reference>
  <results_reference>
    <citation>Zimnik NC, Treadway T, Smith RS, Araneda RC. Î±(1A)-Adrenergic regulation of inhibition in the olfactory bulb. J Physiol. 2013 Apr 1;591(7):1631-43. doi: 10.1113/jphysiol.2012.248591. Epub 2012 Dec 24.</citation>
    <PMID>23266935</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Michele Tagliati, MD</investigator_full_name>
    <investigator_title>Professor and Vice Chairman</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>REM sleep behavior disorder (RBD)</keyword>
  <keyword>Autonomic dysfunction</keyword>
  <keyword>Neurodegeneration</keyword>
  <keyword>Terazosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Parkinson Disease, Secondary</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

